Advances in Translational and
Clinical Research in Meningioma

The DF/HCC Neuro-Oncology Retreat is FREE and open to all members of the DF/HCC community, including fellows, students, technicians, research study assistants and other affiliated staff. The morning sessions will feature short talks that highlight platform technologies available to DF/HCC members, including medicinal chemistry, single-cell sequencing, and cell-based therapies. The second session will feature talks from DF/HCC members with new discoveries relevant to meningioma biology. Afterwards, translational teams will present on biomarker-driven trials for patients with meningioma.

Opening:

8:30 – 8:45 AM: WELCOME AND OVERVIEW

  • Scott Plotkin, MD, PhD (MGH)Tracy Batchelor, MD (BWH)Daphne Haas-Kogan, MD (DFCI/CHB)Mario Suva, MD, PhD (MGH)

Session 1:

8:30 – 9:40 am. DF/HCC Core Overviews for Neuro-Oncology Investigators

  • 8:45 – 9:00 am: Medicinal chemistry core: small molecule drug discovery
    John Hatcher, PhD (DFCI)
  • 9:00 – 9:15 am: Cell manipulation core: developing cell-based therapies
    Sarah Nikiforow, MD, PhD (DFCI)
  • 9:15 – 9:30 am: Single Cell Core: Opportunities for Researchera
    Mandovi Chatterjee, PhD (DFCI)
  • 9:30 – 9:40 am: Questions for session 1 (Moderated by Scott Plotkin, MD)

Session 2:

9:40 am – 11:30 am. Frontiers in biology of meningiomas

  • 9:40 – 10:00 am: Biomarkers in clinical management of meningiomas
    Santagata, Sandro, MD, PhD (BWH)
  • 10:00 – 10:20 am: Tumor heterogeneity in NF2-deficient tumors
    Andrea McClatchey, PhD (MGH)
  • 10:20 – 10:40 am: Targeting signal pathways in meningiomas
    Vijaya Ramesh, PhD (MGH)
  • 10:40 – 11:00 am: Dysregulation of chromatin remodeling in meningiomas
    Cigall Kadoch, PhD (DFCI)
  • 11:00 – 11:20 pm: Unraveling the role of POLR2 variants in meningioma
    Victoria Clark, MD (MGH)
  • 11:20 – 11:30 pm: Questions for session 2 (moderator: Mario Suva, MD, PhD)

Break: 11:30 – 11:45 am


Session 3:

11:45 – 12:30 pm. Ongoing trials for patients with meningioma

  • 11:45 – 12:05 pm: Update on genomically driven trial of meningioma: Alliance A07140
    Priscilla Brastianos, MD (MGH)
  • 12:05 – 12:25 pm: Platform trial for meningioma and other tumors driven by NF2 loss: INTUITT-NF2
    Scott Plotkin, MD, PhD (MGH)
  • 12:25 – 12:30 pm: Questions for session 3 (Moderated by Scott Plotkin, MD)
Hide

RSVP FORM